re CYPB: iwfal's argument is that the drug gets approved for the pain indication on the two previous Phase 3 trials, not the fibro indication. To expand into the fibro indication, there is the ongoing Phase 3.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.